United States Patent 7,420,057 (Flibanserin Form A): Scope, Claims, and Patent-Landscape Position

What does U.S. Patent 7,420,057 claim?

U.S. Patent 7,420,057 is a crystallized-polymorph patent centered on flibanserin 1 Form A. The claims define the protected subject matter using a tight combination of:

Thermal behavior by DSC (an endothermic event at about 161°C)
Solid-state identity by X-ray powder diffraction (XRPD) (a peak list at specified 2θ values)
Downstream product protection via pharmaceutical compositions containing that polymorph in crystalline form
Process dependency for attainment of Form A via a protected synthetic route, with a deprotection step

This is a classic “single polymorph, multiple claim layers” construction. Independent claim coverage is split across (i) the polymorph as material (DSC and XRPD) and (ii) compositions and (iii) attainment process language.

What is the core scope of protection from the claims?

Claim 1: Polymorph defined by DSC

Claim 1 protects:

A crystalline polymorph designated form A of flibanserin
Endothermic maximum at about 161°C during DSC thermal analysis

Scope logic: if a competitor’s Form A has an endotherm “at about 161°C” under DSC, that element maps. The claim does not, on its face, restrict XRPD in claim 1, so the scope turns on whether the accused material is truly “Form A” as characterized by the patent’s definition set.

Claim 2: Polymorph defined by XRPD peak list

Claim 2 protects:

Form A polymorph of flibanserin defined by XRPD pattern
Includes specific d-spacing / angle / relative intensity / counts entries in the specification’s tabular form (as provided in the claim text)

Scope logic: XRPD is the identity anchor with quantitative detail. In enforcement terms, this is the strongest “fingerprint” element.

Claims 3-4: Pharmaceutical compositions (crystalline Form A)

Claim 3: composition comprising Form A according to claim 1, crystalline form, plus optional carriers/excipients.
Claim 4: composition comprising Form A according to claim 2, crystalline form, plus optional carriers/excipients.

Scope logic: composition claims are broad for formulations because they allow “one or more pharmaceutical carriers, diluents or excipients” without limitation. The limiting factor is the crystalline Form A identity.

Claim 5-6: Process for obtaining Form A

Claim 5 protects a process that yields Form A, comprising:
(a) reacting a benzimidazolone 2 where R is an amino protecting group with a piperazine 3 where X is a leaving group selected from:

chlorine, bromine, iodine, methanesulphonate, trifluoromethanesulphonate, para-toluenesulphonate

in solvents selected from:

water, alcohols, mixtures of water with alcohols
polar aprotic solvents
mixtures of polar aprotic solvents with water

with a suitable base, then
(b) cleaving the amino protecting group R under suitable cleaving conditions.

Claim 6 similarly protects the process but ties the outcome to Form A defined by DSC (endotherm ~161°C).

Scope logic: this is a synthesis-route claim layer. Enforcement focuses on whether a competitor’s manufacturing route uses substantially the same protected intermediates/functional choices and performs deprotection under conditions that produces Form A.

Claims 7-8: XRPD peak subset definitions

Claim 7 protects Form A by XRPD pattern that comprises peaks at specific 2θ values:

15.460, 19.140, 19.820, 20.080, 22.630, 24.610, 24.355, 26.575, 28.210, 28.325

Claim 8 repeats the same set but as the claim text “comprising peaks (°2Θ)” at those values.

Scope logic: these claims define Form A using a reduced peak set (10 peaks). This can be advantageous for proof because it can tolerate some variability outside the ten peaks, as long as the critical peaks remain present at matching positions.

Claims 9-10: XRPD broad peak list

Claim 9 protects Form A by XRPD comprising peaks at a larger list, including (as provided):
5.195, 9.045, 9.335, 10.025, 10.595, 11.290, 13.225, 14.595, 15.460, 16.655, 17.085, 17.285, 17.420, 18.140, 18.650, 19.140, 19.820, 20.080, 20.385, 21.215, 21.890, 22.630, 23.210, 24.355, 24.610, 25.995, 25.260, 26.575, 27.155, 27.310, 27.865, 28.210, 28.325, 28.650, 29.520, 30.250, 31.105, 31.905, 32.350, 33.300, 33.640, 34.880, 35.275, 36.055, 36.910, 37.160, 37.680, 39.435, 39.675, 40.325, 40.930, 41.445, 41.990, 42.670, 43.145, 44.190, 46.095, 46.510, 48.305, 48.900, 50.330, 51.035, 53.550, 54.500, 55.420, 56.220, 56.770, 57.405, and 58.500.

Claim 10 repeats the same list.

Scope logic: expanded peak list claims are more stringent for matching, increasing discriminating power against other polymorphs or hydrates. They are also more sensitive to measurement conditions.

Claims 11-14: Composition wrappers tied to XRPD definitions

Claim 11: composition comprising Form A according to claim 7
Claim 12: composition comprising Form A according to claim 8
Claim 13: composition comprising Form A according to claim 9
Claim 14: composition comprising Form A according to claim 10
All require crystalline Form A, plus optional carriers/excipients.

Scope logic: these claims let the patentee align claim strength to different XRPD proof scenarios (ten-peak subset vs full list).

Claims 15-16: Figure-based XRPD definition

Claim 15 protects a Form A polymorph characterized by XRPD “as shown in FIG. 1.”
Claim 16 provides the composition counterpart (FIG. 1 Form A, crystalline form, plus optional excipients).

Scope logic: figure-based claim language can support arguments that the full pattern (as plotted) is part of the protected identity, even if not fully enumerated in a list.

What does this mean for “scope” in practice?

1) The invention is materially constrained to a single polymorph identity

Despite multiple claim forms, the material center is one polymorph: flibanserin Form A. The claims repeatedly return to the same core descriptor set:

DSC endotherm ~161°C
XRPD peak identity (subsets and full lists)
Figure identity (FIG. 1)

2) Claim coverage spans substance, composition, and process attainment

U.S. 7,420,057 covers:

Polymorph as a crystalline material (Claims 1-2, 7-10, 15)
Pharmaceutical compositions containing that polymorph (Claims 3-4, 11-14, 16)
Manufacturing process leading to Form A (Claims 5-6)

3) XRPD claim layers give enforcement flexibility

The patent uses three XRPD “granularity levels”:

10-peak subset (Claims 7-8)
Full enumerated peak list (Claims 9-10)
Figure-based pattern (Claims 15-16)

That enables multiple proof routes against accused products, depending on which characterization data the defendant used or which reference patterns are available.

What is the likely patent landscape structure around flibanserin polymorphs?

Even without additional document details in the prompt, the patent structure itself implies a standard flibanserin polymorph landscape pattern:

A. “Form identity” patents

U.S. 7,420,057 is an example of form-specific crystallinity protection. The claim style indicates it is positioned to block:

direct sale/import of crystalline Form A
formulation kits where the drug substance is crystalline Form A
some generics if they use Form A as the solid-state form and can satisfy the claim identity conditions

B. “Process attainment” patents

Claims 5-6 indicate this patent is also a route-to-form barrier. This matters where competitors might argue that they obtained Form A via “different” steps, but still used the same benzimidazolone/piperazine coupling and deprotection logic (with the claim’s selected leaving groups and solvent/base classes).

C. “Figure/pattern” fallback

The figure-based claim (FIG. 1) expands coverage beyond hard numeric enumeration. If an accused product matches the plotted pattern closely enough, the figure claim can be used alongside or instead of the peak lists.

Claim-by-claim landscape map (what each layer blocks)

Claim group	Protected subject matter	Practical enforcement target
1, 3	Form A via DSC (endotherm ~161°C) + compositions	DSC-confirmed crystalline Form A in API or tablets/capsules
2, 4	Form A via full XRPD tabular pattern + compositions	XRPD-confirmed Form A in finished dosage forms
5-6	Process to obtain Form A via benzimidazolone/piperazine + deprotection	API manufacturing route that yields Form A
7-8, 11-12	Form A via 10 specific XRPD peaks + compositions	Products matching those key peak positions
9-10, 13-14	Form A via extended peak list + compositions	Highly specific XRPD matching against other polymorphs
15-16	Form A “as shown in FIG. 1” + compositions	Pattern-matching approach using the plot as reference

Where are the main risk points for competitors?

1) XRPD identity matching is the primary gate

If a generic or formulation developer uses a solid-state form that meets the XRPD identity (10-peak or full-list requirements), the composition claims become high-risk.

2) “About 161°C” DSC is a second gate

If DSC shows an endothermic maximum near 161°C, the burden shifts to whether the sample is truly Form A. DSC variability exists, but the claim is still direct and centered on a specific thermal event.

3) Process claims can create manufacturing leverage

Even if a competitor tries to avoid composition-level proof issues, they face process claim exposure if:

their route uses the specified intermediate classes and
their deprotection conditions yield the claimed polymorph

Key Takeaways

U.S. Patent 7,420,057 protects flibanserin Form A as a crystalline polymorph using DSC (~161°C endotherm) and XRPD peak-pattern identity.
The patent has three claim layers: material, pharmaceutical compositions, and process attainment.
XRPD is implemented at multiple granularities (10-peak subset, extended peak list, and FIG.-based pattern), creating multiple proof paths and narrowing design-around options.
The primary competitive risk is that an accused API or finished product will test as crystalline Form A under the patent’s DSC and XRPD criteria.

FAQs

1) Does the patent protect flibanserin generally or only Form A?

It protects flibanserin Form A specifically, using DSC and XRPD-defined identity, with downstream composition claims limited to that polymorph in crystalline form.

2) Which claim is strongest for solid-state identity?

The XRPD-defined claims (Claims 2, 9-10) and the peak-list claims (Claims 7-8) provide the most concrete, checkable identity markers.

3) Can a competitor avoid infringement by using the “wrong” excipient mix?

No. The composition claims allow broad ranges of carriers and excipients; the critical limitation is that the formulation contains crystalline Form A.

4) Do the process claims require the exact same leaving groups and solvents?

Claims 5-6 list selected leaving groups, solvent classes, and the need for base and deprotection of an amino protecting group. Use of alternatives that fall outside those enumerated selections can be a design-around focus.

5) How do FIG. 1-based claims affect landscape analysis?

FIG. 1-based claims (Claims 15-16) add a non-enumerated pattern reference that can support arguments of identity through the plotted XRPD pattern rather than only through the numeric peak lists.

References

[1] U.S. Patent No. 7,420,057. “Crystalline polymorph of flibanserin.” (Claims provided in prompt).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	01118593	Aug 2, 2001
	01130180	Dec 19, 2001

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	036208	⤷ Start Trial
Argentina	077416	⤷ Start Trial
Austria	288911	⤷ Start Trial
Australia	2002331361	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,420,057

Summary for Patent: 7,420,057